Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Looking at how these situations compare provides helpful perspective
Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway
Exenatide BID demonstrated similar HbA1c improvement as insulin glargine over 26 weeks (1.25% vs 1.26%) but led to weight loss rather than weight gain of 3 kg with insulin
With a sharp focus on metabolic diseases, the company is poised to lead the booming obesity market
Increasing awareness of diabetes and obesity, coupled with rising disposable incomes and government initiatives to improve chronic disease management, are key factors driving the significant growth potential of the GLP-1 receptor agonist market in the Asia Pacific region
Repeated-dose oral N-acetylcysteine in Parkinsons disease: pharmacokinetics and effect on brain glutathione and oxidative stress
US$ 24.69
US$ 20.84
US$ 20.99
US$ 23.75
US$ 26.57
